Heart drug swap tested for safer symptom control

NCT ID NCT07600177

Recruiting now Disease control Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with a type of heart disease called obstructive hypertrophic cardiomyopathy can safely switch from one medication (mavacamten) to another (aficamten). The goal is to keep the heart working better and reduce symptoms. About 40 adults who are already taking mavacamten will be enrolled and closely monitored for side effects and heart function changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY (HCM)

Contacts and locations

Locations

Oregon Health & Science University
RECRUITING

Portland, Oregon, 97239, United States
St. Luke's Hospital - Mid America Heart Institute
NOT_YET_RECRUITING

Kansas City, Missouri, 64111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.